AgingResearch.NewsJoin free

Phase 2Completed

The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder (CBG)

CBG and Attention: A Double-Blind, Randomized, Placebo-Controlled Trial Examining the Effects of Cannabigerol on Indicators of Attention-Deficit/Hyperactivity Disorder

Sponsor
University of Arkansas, Fayetteville (Academic or other)
Enrollment
67 enrolled
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Cannabigerol; Placebo
Ages
adults
Registry
NCT06115603

Full record on ClinicalTrials.gov

From the registry

The goal of this clinical trial is to evaluate the effects of Cannabigerol (CBG) on indicators of Attention-Deficit/Hyperactivity Disorder (ADHD) in a sample of participants indicating/reporting symptoms associated with ADHD. The main question it aims to answer is: Does CBG reduce ADHD-related indicators relative to placebo? Participants will administer an acute dose of placebo or 80mg CBG and complete outcome measures at 45 minutes (PANAS only) and 75 minutes. Daily surveys to monitor safety will be administered for one week following administration.

Primary outcomes

  • Sustained Attention to Response Task
  • Trail Making Test-Parts A and B (TMT-A&B)
  • Digit Symbol Substitution Test (DSST)
  • Rey Auditory Verbal Learning Test (AVLT)

History

  1. Last registry update

  2. Study completion

  3. Primary completion

  4. Started

  5. Registered